T he findings of positron emission tomography (PET), performed very early during ABVD chemotherapy have been proven to be the most important prognostic information for predicting treatment outcome in patients with Hodgkin's lymphoma treated with this chemotherapeutic regimen. 1,2 However, many issues remain controversial, and shared, standard criteria for interpreting PET findings have not yet been determined. It is still unclear, for instance, whether a qualitative approach based on visual assessment should be used, or whether a semi-quantitative approach involving standardized uptake value (SUV) analysis of 2-[ 18 F]fluoro-2-deoxyglucose (FDG) is preferred for PET reporting. In this issue of the Journal, Dann et al. propose a new scoring system for the interpretation of interim PET scans in patients with Hodgkin's lymphoma treated with either ABVD or BEA-COPP chemotherapy. 3 Hodgkin's lymphoma is a curable neoplasm given that, after a minimum follow-up of 6 years, more than 90% of patients are still alive and 80% are considered cured. 4 These rewarding results have been obtained by a combination of factors influencing treatment outcome in different ways. These factors can be briefly summarized as: (i) increasing accuracy of staging procedures; (ii) different treatment strategies tailored to well-defined categories of patients with different risks of treatment failure; (iii) the peculiar neoplastic tissue architecture in Hodgkin's lymphoma, which differs from that in more common subtypes of lymphoma such as diffuse large B-cell lymphoma and follicular lymphoma; and (iv) the marked chemosensitivity and radiosensitivity of the tumor. It can be hypothesized that there is a close relationship between the last two factors: indeed, the tumor tissue in Hodgkin's lymphoma is composed of a few, scattered neoplastic cells called Hodgkin and Reed-Sternberg (HRS) cells, accounting for less than 1% of the total cell count found in biopsy specimens, surrounded by a overwhelming population of non-neoplastic mononuclear bystander cells. 5 These latter cells are recruited by chemokines produced by the HRS cells and induce expression of anti-apoptotic proteins in HRS cells and their immortalization via a paracrine loop. 6 The chemokines responsible for recruitment of cells to the microenvironment, thymus and activation-regulated chemokines (TARC-CCL7) and macrophage-derived chemokines (MDC), selectively attract CCR4-expressing cell subsets, including eosinophils, histiocytes, macrophages, plasma cells, and Th2 and Treg lymphocytes, which are all readily detected at tumor sites. There is convincing evidence that forced expression of CCR4 by these various subsets of cells provides the cells with the capacity to migrate along a TARC gradient, so that the function of the CCR4 receptor is not restricted to the subset of T cells on which it is physiologically expressed. 7 These cells are metabolically very active, produce chemokines to recruit new accessory cells and block apoptosis of the HRS. 8 The role of macrophages in recruiting ...